Damia Tormo

Damia Tormo serves as a Partner at Sangha Capital SA, focusing on investments in technology start-ups aligned with the United Nation’s Sustainable Development Goals. Additionally, Damia holds multiple director roles at Integra Therapeutics, Minoryx Therapeutics, Aleta Biotherapeutics, and Tyris tx, contributing to advancements in gene writing tools, therapies for orphan genetic diseases, immuno-oncology, and innovative genetic treatments. As a Founder and Director at Syngoi Therapeutics, Damia oversees the production of synthetic DNA. Damia is also a General Partner at COLUMBUS VENTURE PARTNERS, emphasizing investment in disruptive early-stage science. Board membership at Algenex S.L. and leadership at Fundación Columbus underscore a commitment to biotech innovation and community service. Educational qualifications include a PhD in Molecular Genetics and Immunology from The University of Bonn and a Master's in Biotechnology Management from IE Business School.